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An 80-year-old woman with a positive RT-PCR (reverse
transcription polymerase chain reaction) for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) on naso-
pharyngeal swabwas admitted to our COVID-19 department
during the pandemic with fever, dyspnea, and need for
oxygen therapy; two large hematomas were present bilater-
ally in the axillary zones. Her past medical history included
Crohn’s disease diagnosed 30 years ago after perforation of
the ascending colon, hypertension, bilateral hip replace-
ment, appendectomy, and tonsillectomy; no history of
bleeding complications was reported during or after surgical
interventions or in the postpartum, and no history of men-
orrhagia or easy-bruising. One month and a half before
admission, she underwent right knee replacement surgery
with no complications, no blood units, or plasma trans-
fusions were required. At that time complete blood count
and screening clotting test were within normal range.
Investigations on admission were as follows: white blood
cell 11,380/mm3 (Neu 10,790; Ly 240); hemoglobin 8 g/dL;
mean corpuscular volume 89 fL; platelets 251,000/mm3; PTr
1.16 (n.v. 0.80–1.21); PTTr 1.49 (n.v. 0.80–1.18); D-dimer
2,161 μg/L (n.v.< 790);fibrinogen 455mg/dL (n.v. 180–400);
C-reactive protein 78.4mg/L (n.v.< 5.0). A chest computed
tomography scan outlined a picture of bilateral interstitial
pneumonia with ground-glass areas and thickening of inter-
stitium, consistent with a viral infection; moreover, the
presence of hyperdense hematomas in the axillary zones
was recorded (thickness 20–30mm), no active bleeding was
detected. Antiretroviral therapywith darunavir and ritonavir
was started; hydroxychloroquine was not administered for
prolonged QTc on electrocardiogram. Enoxaparin 4000
IU/day was introduced for prophylaxis and continued until
hospital discharge.
The isolated prolonged PTTr (silica) was confirmed in day
þ5 and þ7 from admission (1.30 and 1.42, respectively), PTTr
(ellagic acid, reagent sensible to factors VIII, IX, XI deficiency)
was prolonged too, so a PTT MIX test was required: the PTTr
MIX at time 0was normal but PTTrMIX at 2 hours at 37°Cwas
above the normal range, consistent with the presence of an
inhibitor (►Table 1); the fXI activity was 37% (n.v. 55–150)
while fVIII, fIX, and fXII were in the normal range. Detection of
antiphospholipid antibodies (lupus anticoagulant, anticardio-
lipin, and anti-β2 glycoprotein I) resulted negative. The PTT
MIX test and clotting factors activity was retested 3 days later
and the presence of an acquired deficiency of fXI was con-
firmed. Patient was discharged in good clinical conditions
more than1monthafter admission, no thromboticor bleeding
complications occurred during hospitalization.
Inhibitors against clotting factors generally occur in
patients with severe congenital deficiencies who underwent
periods of replacement therapy. Acquired factor inhibitors in
the absence of congenital deficiency are rare events, among
them the production of autoantibodies inhibiting fVIII is the
most frequent acquired bleeding disorder. On the contrary,
inhibitors against fXI have been reported only anecdotally in
literature mostly associated to autoimmune disorders, that
is, systemic lupus erythematosus,1 rheumatoid arthritis,2
Crohn’s disease,3 membranoproliferative glomerulonephri-
tis,4 or in association with malignancies, that is, chronic
lymphocytic leukemia,5 gastrointestinal adenocarcinoma,3
and thymoma6; a case of transient acquired fXI deficiency
after gynecological surgery has been reported.7 The risk of
bleeding in conditions of fXI deficiency is relatively low and
correlation between factor levels and symptoms is very poor;
in these persons hemorrhage is usually provoked, exacerbat-
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In the classical chart of the intrinsic pathway of coagula-
tion waterfall the fXIIa activates the zymogen fXI which in
turn activates fIX and so, through a series of enzymatic
reactions, it conducts to thrombin formation. It is nowadays
well documented that fXII has only a marginal role in the
hemostasis in vivo, contributing more to inflammation and
pathologic coagulation; in fact, fXI seems to be activated in a
stronger way directly by thrombin, thus supporting and
amplifying thrombin formation in loop.10 Moreover, it has
also been shown how fXIa activates fXII after tissue factor-
initiated coagulation (via extrinsic pathway).11 Maybe coag-
ulation is not a waterfall but a whirlpool!
But fXI is not only a component of the coagulation
pathway, it also participates to the process of contact activa-
tion by mean of the bradykinin-generating kallikrein–kinin
system (KKS) (including fXII, prekallikrein PK, high molecu-
lar weight-kininogen HK, and C1 esterase inhibitor C1INH)
contributing in this way to several host-defenses and to the
initial response to infection: in fact, the inflammatory re-
sponse to viral infections is in part mediated by contact
activation and it has already been demonstrated how hanta-
virus and herpes simplex virus 1 can lead to the activation of
KKS pathway.12 The fXI, together with fXII, seems to have a
pivotal role in this context.13 In a sepsis setting of fXI
deficient mice, Bane et al have shown how a reduced early
cytokine response and KKS activation conduct to a survival
benefit compared with wild-type mice.11,14
Reconnecting to the case reported above, the reason for the
occurrence of inhibitors production against fXI during SARS-
CoV-2 infection is still not clear to us, but maybe we can
speculate that the inhibition of fXI could be a means of the
immune system to try to turn off a sustained inflammatory
overresponse against an infective agent which can otherwise
conduct to deleterious effects for the host.Why not to consider
this patient, with an autoimmune milieu (Crohn’s disease), as
evolutionaryadvantaged in this conditionhaving thepossibility
to counterbalance the state of hypercoagulability and inflam-
mation (the so-called, thromboinflammation15)? Why not to
actdirectlyagainst fXI, inhibiting it andononesideblocking the
pathological coagulation loopwithamild riskofhemorrhage, as
already demonstrated16,17 and on the other side disrupting the
mechanism driving to the uncontrolled inflammatory over-
response by blunting KKS and complement activation?
By our, at this point, everyday experience and from the still
scanty literature in this regard it seems tous that patientswith
severe pneumonias by SARS-CoV-2 can develop a hypercoag-
ulable condition driving to a higher risk for (micro)vascular
thrombosis, still to demonstrate18–21; if true, considering the
interface role of fXI in vascular thrombosis and inflammation,
the development of therapies inhibiting this factor could be an
intriguing leverage on which to act for trying to improve
microvascular perfusion, reduce inflammation, and protect




1 Wool GD, Treml A, Miller JL. Acquired factor XI deficiency and
therapeutic plasma exchange. J Clin Apher 2018;33(03):427–430
2 Reece EA, Clyne LP, Romero R, Hobbins JC. Spontaneous factor XI
inhibitors. Seven additional cases and a review of the literature.
Arch Intern Med 1984;144(03):525–529
3 Kyriakou DS, Alexandrakis MG, Passam FH, et al. Acquired inhib-
itors to coagulation factors in patients with gastrointestinal
diseases. Eur J Gastroenterol Hepatol 2002;14(12):1383–1387
4 McManus MP, Frantz C, Gailani D. Acquired factor XI deficiency in
a child with membranoproliferative glomerulonephritis. Pediatr
Blood Cancer 2012;59(01):173–175
Table 1 Coagulatory and inflammatory parameters
Unit Ref. March 17 March 21 March 23 March 26 April 7 April 12 April 18 April 21
Thrombin
time
Ratio [< 1.20] 1.08
aPTTr
(silica)
Ratio [0.80–1.18] 1.49 1.30 1.42 1.55 1.40 1.30 1.30 1.24
aPTT MIX
time 0







Factor VIII % [50–200] 120
Factor IX % [65–140] 101
Factor XI % [55–150] 37 38.5
Factor XII % [55–180] 63
D-dimer μg/L [< 790] 2,161 3,501 2,471 2,004 2,183
Fibrinogen mg/dL [180–400] 455 541 505 541 568
CRP mg/L [< 5.0] 78.4 55.6 12.7 34.7
Abbreviations: aPTTr, activated partial thromboplastin time ratio; CRP, C-reactive protein.
TH Open Vol. 00 No. 0/2020
Acquired Factor XI Deficiency during SARS-CoV-2 Infection Andreani et al.e234
5 GoodrickMJ, PrenticeAG, Copplestone JA, PamphilonDH, BoonRJ.
Acquired factor XI inhibitor in chronic lymphocytic leukaemia. J
Clin Pathol 1992;45(04):352–353
6 Jethava Y, Alamelu J, Rangarajan S, Lang-Lazdunski L, van derWalt
J, Fields P. Acquired agranulocytosis and factor XI deficiency in
association with thymoma. J Clin Oncol 2011;29(20):e604–e606
7 Castaman G, Ruggeri M, Rodeghiero F. Acquired transitory factor
XI inhibitor after gynaecological surgery. Haemophilia 2008;14
(03):643–644
8 Wheeler AP, Gailani D. Why factor XI deficiency is a clinical
concern. Expert Rev Hematol 2016;9(07):629–637
9 Peyvandi F, Palla R, Menegatti M, et al; European Network of Rare
Bleeding Disorders Group. Coagulation factor activity and clinical
bleeding severity in rare bleeding disorders: results from the
European Networkof Rare Bleeding Disorders. J Thromb Haemost
2012;10(04):615–621
10 Emsley J, McEwan PA, Gailani D. Structure and function of factor
XI. Blood 2010;115(13):2569–2577
11 Bane CE Jr, Ivanov I, Matafonov A, et al. Factor XI deficiency alters
the cytokine response and activation of contact proteases during
polymicrobial sepsis in mice. PLoS One 2016;11(04):e0152968
12 Long AT, Kenne E, Jung R, Fuchs TA, Renné T. Contact system
revisited: an interface between inflammation, coagulation, and
innate immunity. J Thromb Haemost 2016;14(03):427–437
13 Shatzel JJ, DeLoughery EP, Lorentz CU, et al. The contact activation
system as a potential therapeutic target in patientswith COVID-19.
Res Pract Thromb Haemost 2020;4(04):500–505
14 Tucker EI, Verbout NG, Leung PY, et al. Inhibition of factor XI
activation attenuates inflammation and coagulopathy while im-
proving the survival of mouse polymicrobial sepsis. Blood 2012;
119(20):4762–4768
15 Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflam-
mation: challenges of therapeutically targeting coagulation and
other host defense mechanisms. Blood 2019;133(09):906–918
16 Chen W, Carvalho LP, Chan MY, Kini RM, Kang TS. Fasxiator, a
novel factor XIa inhibitor from snake venom, and its site-specific
mutagenesis to improve potency and selectivity. J Thromb Hae-
most 2015;13(02):248–261
17 Büller HR, Bethune C, Bhanot S, et al; FXI-ASO TKA Investigators.
Factor XI antisense oligonucleotide for prevention of venous
thrombosis. N Engl J Med 2015;372(03):232–240
18 Magro C, Mulvey JJ, Berlin D, et al. Complement associated micro-
vascular injuryand thrombosis in thepathogenesis of severeCOVID-
19 infection: a report of five cases. Transl Res 2020;220:1–13
19 Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological
findings and complications of COVID-19. Am J Hematol 2020;95
(07):834–847
20 Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of
thrombotic complications in critically ill ICU patients with
COVID-19. Thromb Res 2020
21 Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of
COVID-19 patients in intensive care unit: a report of thromboe-
lastography findings and other parameters of hemostasis. J
Thromb Haemost 2020. Doi: 10.1111/jth.14850
TH Open Vol. 00 No. 0/2020
Acquired Factor XI Deficiency during SARS-CoV-2 Infection Andreani et al. e235
